These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26799344)

  • 21. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strengthening standards, transparency, and collaboration to support medicine evaluation: Ten years of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP).
    Kurz X; Perez-Gutthann S;
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):245-252. PubMed ID: 29327451
    [No Abstract]   [Full Text] [Related]  

  • 23. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ongoing challenges in pharmacovigilance.
    Dal Pan GJ
    Drug Saf; 2014 Jan; 37(1):1-8. PubMed ID: 24264884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medicine Safety Monitoring in Pediatric Population in India.
    Kaur I; Kalaiselvan V; Singh GN
    Indian J Pediatr; 2016 May; 83(5):479-80. PubMed ID: 26634262
    [No Abstract]   [Full Text] [Related]  

  • 27. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacovigilance in developing countries (part II): a path forward.
    Elshafie S; Roberti AM; Zaghloul I
    Int J Clin Pharm; 2018 Aug; 40(4):764-768. PubMed ID: 29322474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Causality assessment in reports on adverse drug reactions. Algorithm of Spanish pharmacovigilance system].
    Aguirre C; García M
    Med Clin (Barc); 2016 Nov; 147(10):461-464. PubMed ID: 27450163
    [No Abstract]   [Full Text] [Related]  

  • 31. The role and strategy of ISoP in global pharmacovigilance.
    Olsson S; Harrison-Woolrych M
    Int J Clin Pharm; 2018 Aug; 40(4):740-743. PubMed ID: 30073610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EUROmediCAT Recommendations for European Pharmacovigilance concerning safety of medication use in pregnancy.
    EUROmediCAT Steering Group
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():3-7. PubMed ID: 26395593
    [No Abstract]   [Full Text] [Related]  

  • 33. A cross-sectional study of adverse drug reactions reporting among doctors of a private medical college in Bihar, India.
    Panja B; Bhowmick S; Chowrasia VR; Bhattacharya S; Chatterjee RN; Sen A; Sarkar M; Ram AK; Mukherjee PK
    Indian J Pharmacol; 2015; 47(1):126-7. PubMed ID: 25821329
    [No Abstract]   [Full Text] [Related]  

  • 34. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
    Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
    Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety reporting through a comprehensive and pragmatic pharmcovigilance process for India and emerging markets: an industry perspective.
    Swamy S; Mourya M; Kadhe G; Mane A; Sawant S
    Expert Opin Drug Saf; 2015; 14(9):1409-20. PubMed ID: 26292785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey.
    Stergiopoulos S; Fehrle M; Caubel P; Tan L; Jebson L
    Pharmaceut Med; 2019 Dec; 33(6):499-510. PubMed ID: 31933240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is pharmacovigilance of biologicals cost-effective?
    Claus B
    Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.